New developments and strategies for success in dealing with FDA, OIG, SEC, EMEA, and more.
|
May 6, 2013
By:
Nathan Jessop
While not as bleak as believed, the outlook of European biotech sector is struggling compared with its US counterpart.
|
May 6, 2013
By:
Jill Wechsler
Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.
|
April 1, 2013
By:
Reflector
The European Union's attempt to update its transparency rules sparks new debate.
|
March 1, 2013
By:
Reflector
European Commision blocks the authorization of a life-saving liver drug outside of France.
|
March 1, 2013
By:
Jill Wechsler
Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.
|
|
February 1, 2013
By:
Julian Upton
After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. Julian Upton reports.
|
|
January 1, 2013
By:
Ben Comer
Compliance officers have risen into management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.
|
December 1, 2012
By:
William Looney
Europe's chief regulator charts a strategy from many moving parts. Dr Guido Rasi talks to Pharm Exec's William Looney.
|
December 1, 2012
At two years and counting, what's the secret of success in negotiating pricing under the new AMNOG legislation?
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
